The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis

Figure 7

Forest plot comparing marrow microvessel density (MVD) between initial and recurrent MM patients both treated effectively with the T-VAD regimen.